Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vericiguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 known ✓ | Q02108 | 2/20 | 0.55 |
| ▸ | GUCY1B1 known ✓ | Q02153 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 17/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vericiguat SCHEMBL29379616 | 1.00 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL429958 | 1.00 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL30395636 | 1.00 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL30277583 | 0.99 | ADORA3 (0.56) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906124 | 0.99 | ADORA3 (0.56) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906117 | 0.97 | ADORA3 (0.54) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906109 | 0.97 | ADORA3 (0.54) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906114 | 0.97 | ADORA3 (0.54) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906094 | 0.95 | GUCY1A1 (0.53) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Vericiguat SCHEMBL29906089 | 0.95 | ADORA3 (0.53) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | ADVERIO PHARMA GMBH (DE) | 2026-05-26 | — | — | US | claimed |
| US-12427131-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-30 | — | — | US | claimed |
| US-20250276969-A1 | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT | MOEHS IBERICA, S.L. (ES) | 2025-09-04 | — | — | US | claimed |
| US-12172996-B2 | Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof | ADVERIO PHARMA GMBH (DE) | 2024-12-24 | — | — | US | claimed |
| EP-3525779-B1 | COMBINATION CONTAINING THE SGC STIMULATOR VERICUGUAT AND THE MINERALCORTICOID RECEPTOR ANTAGONIST FINERENONE | Bayer Pharma AG (DE) | 2024-06-05 | — | — | EP | claimed |
| CN-115175666-B | Nanoformulation of methyl {4, 6-diamino-2- [ 5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b ] pyridin-3-yl ] pyrimidin-5-yl } carbamate | 阿德弗里奥药品有限责任公司 | 2024-04-26 | — | — | CN | claimed |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-07-13 | — | — | US | claimed |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | claimed |
| EP-4165028-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE | Adverio Pharma GmbH (DE) | 2023-04-19 | — | — | EP | claimed |
| US-20230067593-A1 | NANOFORMULATIONS OF METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-03-02 | — | — | US | claimed |
| EP-4099987-A1 | NANOFORMULATIONS OF METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE | Adverio Pharma GmbH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-11439628-B2 | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | claimed |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2022-09-13 | — | — | US | claimed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | ADVERIO PHARMA GMBH (DE) | 2026-05-26 | — | — | US | disclosed |
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | ADVERIO PHARMA GMBH (DE) | 2026-05-26 | — | — | US | disclosed |
| US-20220048907-A1 | METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE ACTIVE COMPOUND PRODUCT HAVING IMPROVED PROPERTIES, PRODUCTION AND FORMULATION THEREOF | ADVERIO PHARMA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439628-B2 | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | MC2R, NR3C2, NR3C1 | GUCY1A1 45/4885GUCY1B1 89/4885ADORA3 1773/4885 |
| US-20230067593-A1 | NANOFORMULATIONS OF METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | KMT5B, SP1, KDM5B | GUCY1A1 2587/4885GUCY1B1 2232/4885ADORA3 4223/4885 |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | GUCY1A1 1337/4885GUCY1B1 1025/4885ADORA3 1633/4885 |
| US-12172996-B2 | Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof | AZI2, KDM4D, Q6ZSR9 | GUCY1A1 1499/4885GUCY1B1 1110/4885ADORA3 3264/4885 |
| US-20250276969-A1 | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT | DPYD, AGT, DNTT | GUCY1A1 1117/4885GUCY1B1 1364/4885ADORA3 3020/4885 |
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | POLL, F9, DNMT3B | GUCY1A1 952/4885GUCY1B1 635/4885ADORA3 3359/4885 |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | POLL, DNMT3B, MTAP | GUCY1A1 1281/4885GUCY1B1 798/4885ADORA3 2850/4885 |
| US-12427131-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | MME, ECE1, REN | GUCY1A1 8/4885GUCY1B1 16/4885ADORA3 2019/4885 |
| US-20220048907-A1 | METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE ACTIVE COMPOUND PRODUCT HAVING IMPROVED PROPERTIES, PRODUCTION AND FORMULATION THEREOF | AZI2, KDM4D, Q6ZSR9 | GUCY1A1 1499/4885GUCY1B1 1110/4885ADORA3 3264/4885 |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | NR3C2, GUCY1A1, GUCY1A2 | GUCY1A1 2/4885GUCY1B1 7/4885ADORA3 785/4885 |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | GUCY1A1 8/4885GUCY1B1 16/4885ADORA3 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.